Evidence map›Paper›PMID 33369708›Full record

ArticleHepatology international2020

Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease.

Nahla Azzam, Yazed AlRuthia, Othman Alharbi, Abdulrahman Aljebreen, Majid Almadi, Edward V Loftus

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Nahla AzzamDivision of Gastroenterology, Department of Medicine, King Saud University Medical City, King Saud University, Po Box 2925, 12372, Riyadh, Kingdom of Saudi Arabia. nazzam@ksu.edu.sa.ORCID http://orcid.org/0000-0002-2097-289X
Yazed AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Po Box 2925, 12372, Riyadh, Kingdom of Saudi Arabia.
Othman AlharbiDivision of Gastroenterology, Department of Medicine, King Saud University Medical City, King Saud University, Po Box 2925, 12372, Riyadh, Kingdom of Saudi Arabia.
Abdulrahman AljebreenDivision of Gastroenterology, Department of Medicine, King Saud University Medical City, King Saud University, Po Box 2925, 12372, Riyadh, Kingdom of Saudi Arabia.
Majid AlmadiDivision of Gastroenterology, Department of Medicine, King Saud University Medical City, King Saud University, Po Box 2925, 12372, Riyadh, Kingdom of Saudi Arabia.
Edward V LoftusDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA.
King Saud Medical City · SAKing Saud University · SAMayo Clinic in Arizona · USMontreal General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purpose of the studyPrimary sclerosing cholangitis (PSC) is the most common hepatobiliary manifestation of inflammatory bowel disease (IBD). Magnetic resonance cholangiography (MRC) has become the primary diagnostic modality for PSC. However, data on radiological progression over time of large-duct PSC-IBD are limited.

methodsWe performed a nested case-control study to estimate the frequency of PSC in adult patients with IBD from a Middle Eastern population to assess the risk factors associated with major disease progression (formation of dominant strictures or cholangiocarcinoma) over time.

resultsData of IBD patients who were registered in the Saudi IBD Information System at tertiary care center were analyzed. Among 960 patients [477 ulcerative colitis (UC); 483 Crohn's disease (CD)], 40 PSC-IBD patients with at least two MRC performed in a one-year interval were matched with 141 IBD patients without PSC. The frequency of PSC was 4.1%. UC patients (6.2%) compared to CD (2%), 65% had extensive colitis. The incidence rate of PSC among our cohort was increased from 2.62 to 10 per 1000 patient-years between 2005 and 2019. MRC features stabilized in (46.7%); worsened in (36.9%) and 15.4% of patients developed CCA. Alkaline phosphatase (ALP) levels of PSC patients who had major changes or CCA increased significantly after 44 months of follow-up (p = 0.01). The propensity score adjusted showed that hospitalization rate among PSC patients was higher than their non-PSC counterparts (OR 8.24; 95% CI 3.16-21.47; p < 0.01).

conclusionALP rise and hospitalization history as clinical outcome were the only factors associated with PSC-IBD major progression on MRCP.

Indexed as

Cholangitis, SclerosingInflammatory Bowel DiseasesBile Duct NeoplasmsBile Ducts, IntrahepaticCase-Control StudiesColitis, UlcerativeHumansCrohn’s diseaseDominant stricturesInflammatory bowel diseaseMagnetic resonance cholangiographyMiddle Eastern populationPrimary sclerosing cholangitisUlcerative colitis

Identifiers

PMID33369708
OpenAlexW3115983594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.